In September BC Diabetes blogged on the astounding outcome of the EMPA-REG OUTCOME® study indicating a 32% reduction in all- cause mortality in high risk individuals with Type 2 diabetes randomized to empagliflozin 10 or 25 milligrams compared to placebo.

This report on the presentation of the renal outcomes of the same study from San Diego last week. It indicates the same benefit in patients with reduced renal function as well as reductions in progression of renal disease in the same group.

This study therefore shows broad benefit to patients at high cardiovascular risk receiving empagliflozin. bcdiabetes considers this a game changer such that all patients and high risk should be considered for this drug.

Translate »